Navigation Links
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Date:12/3/2007

Selected Therapy Can Advance to Phase III Clinical Trial

PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, today announced positive Phase II data for a combination trial involving AL-08, the Company's second generation proprietary drug candidate for the treatment of ALS. The purpose of the trial was to determine which of two compounds used in combination with AL-08 would yield the most favorable results, so that the Company could proceed to a Phase III trial. Results were presented by Paul H. Gordon, MD of Columbia University in a presentation titled "Combination Drug Selection Trial in Amyotrophic Lateral Sclerosis" at the 18th International Symposium on ALS/MND in Toronto, Canada on December 3, 2007. This study was funded by the ALS Association, Ride for Life, and the Russ Bowen and Spina Family Foundations.

The Phase II trial evaluated the neuroprotective capacity of two combinations, AL-08 and minocycline versus AL-08 with celecoxib, using group sequential design and a natural history control group for a futility analysis. The primary objective of the trial was selection of a treatment based on which drug combination appeared to slow deterioration in the ALS- Functional Score. Results showed that patients taking the AL-08/celecoxib combination showed a smaller mean decline in ALS- Functional Score compared to those taking the AL- 08/minocycline combination. Results also showed that the AL-08/celecoxib combination was non-futile compared to historical controls, and merits further evaluation. The trial was concluded ahead of schedule after the first pool of patients met the selection criteria.

"We are encouraged that the AL-08/celecoxib combination showed less of a decline in ALS-Functional Score compared to AL-08 and minocycline and historical control. Since the dif
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
2. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...., Sept. 5 /PRNewswire-USNewswire/ -- A team of,re...at U.S. immigrants from,India and Pakistan take on...heir risks of prostate cancer among male immigrant...r and prostate cancer develop due to many reasons,...jor role in these cancers,",said Jame Abraham, M.D...
(Date:9/4/2008)... in TaqMan(R) real-time PCR testing for the diagno...NTON, Calif., Sept. 4 /- The U.S. Foo...he COBAS(R) TaqMan(R) HBV Test,the first assay fo...he U.S.,The test uses Roche,s real-time PCR techno...NA in a patient,s blood. Doctors may use viral loa...
(Date:9/4/2008)...and, September 4 /- Axentis Pharma AG...s the safety and tolerability,of a new therapeutic...,infection in cystic fibrosis patients. The new fo...to be delivered directly to the site of,infection....ts of two,different doses of the new drug. Initial...
(Date:9/3/2008)...a, Sept. 4 /Xinhua--,Pharma...) today announced,that it has enrolled the first s...ial evaluating Bronchitol in cystic fibrosis suffe... hospitals across North,America, Argentina and Ger...xis seeks approval to market Bronchitol for cystic...
Breaking Medicine Technology:Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3Body Image is a Concern for Students of All Ages 23875 1Body Image is a Concern for Students of All Ages 23875 2Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 1Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 2Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 1Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 2Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 1Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 2
... II GBM study presented at ASCO with cediranib - a... quarter of patients alive,and progression- free a...e/ -- Data for the,investigational agent cediranib...ing of the American Society of Clinical Oncology,(...blastoma (GBM),an invasive form of brain tumor wi...
...itive data on subcutaneous administration show pot...atients -, CHICAGO, June 04, 2007 /PRNewswire-Firs...nnounced the presentation of positive,data for VEL...,multiple myeloma (MM) who have received at least ... a Phase II trial for subcutaneous,(SC) administra...
Other Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 7
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...responsible for checking the profits and safety of... to the NHS. They have to monitor that only brande...ould be reasonable. The Pharmaceutical Price Regu...nization which monitors and legislates the agreeme...
...ve come up with a disaster-planning guide to help ...nted by tropical storms, hurricanes, tidal waves a...world, people are vulnerable to some sort of natur...ke, flood, hurricane, or tornado. In addition, ter...
...ed over the increasing malfunction of heart device... deaths between 1990 and 2002. The Food and Drug A...ng with physicians and heart-device manufacturers ...llators had failed between 2000 and 2003. Same num...
...he damages in the heart from the use of stem cells...s from mice to repair heart damage in sheep, repor...sue of The Lancet. Heart failure is a major cause ...es, occurring when cells within the heart are dama...
Other Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device.
Clinicians are demanding smaller, higher performing systems specifically designed to meet their clinical and operational challenges. The new Philips HD11 XE system provides a powerful architecture fo
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea
InfinixTM CF-i/SP brings revolutionary flexibility to floor-mounted X-ray systems. The unique design enables operators to move the C-arm around the exam table as needed to obtain the optimal angle fo
Medicine Products: